Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 1980; 43(02): 095-098DOI: 10.1055/s-0038-1650025 Original Article Schattauer GmbH Stuttgart A Quarter Century with Mr. Hageman[*] Oscar D Ratnoff M. D. The Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, U. S. A. › Institutsangaben Artikel empfehlen Abstract als PDF herunterladen Artikel einzeln kaufen Keywords KeywordsHageman factor - Factor XI - Plasma prekallikrein - High molecular weight kininogen PDF (1130 kb) Referenzen References 1 Ratnoff OD, Hartmann RC, Conley CL. Studies on a proteolytic enzyme in human plasma. V. The relationship between the proteolytic activity of plasma and blood coagulation. J Exp Med 1950; 91: 123-133 2 Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 603-613 3 Margolius Jr AJ, Ratnoff OD. Observations on the hereditary nature of Hageman trait. Blood 1956; 11: 565-569 4 Bennett B, Ratnoff OD, Holt JB, Roberts HR. Hageman trait (factor XII deficiency): a probable second genotype inherited as an autosomal dominant characteristic. Blood 1972; 40: 412-415 5 Smink McL M, Daniel TM, Ratnoff OD, Stavitsky AB. Immunologic demonstration of a deficiency of Hageman factor-like material in Hageman trait. J Lab Clin Med 1967; 69: 819-832 6 Saito H, Scott JG, Movat HZ, Scialla SJ. Molecular heterogeneity of Hageman trait (factor XII deficiency): evidence that 2 of 49 cases are cross-reacting material positive (CRM+). J Lab Clin Med 1979; 94: 256-265 7 Glueck HI, Roehill Jr W. Myocardial infarction in a patient with Hageman (factor XII) defect. Ann Int Med 1966; 64: 390-396 8 Hoak JC, Swanson LW, Warner ED, Connor WE. Myocardial infarction associated with severe factor-XII deficiency. Lancet 1966; 2: 884-886 9 Ratnoff OD, Busse Jr RJ, Sheon RP. The demise of John Hageman. New Engl J Med 1968; 279: 760-761 10 Donaldson VH, McAdams AJ, Stratman EJ, Glueck HI. Fatal vascular disease in a patient with Hageman trait and a connective tissue disorder. New Engl J Med 1977; 297: 1237 (letter) 11 Biggs R, Sharp AA, Margolis J, Hardisty RM, Stewart J, Davidson WM. Defects in the early stages of blood coagulation: a report of four cases. Brit J Haem 1958; 4: 177-191 12 Soulier J-P, Prou-Wartelle O. New data on Hageman factor and plasma thromboplastin antecedent: the role of 'contact' in the initial phase of blood coagulation. Brit J Haemat 1960; 6: 88-101 13 Ratnoff OD, Rosenblum JM. Role of Hageman factor in the initiation of clotting by glass. Amer J Med 1958; 25: 160-168 14 Schiffman S, Rapaport SI, Ware AG, Mehl JW. Separation of plasma thromboplastin antecedent (PTA) and Hageman factor (HF) from human plasma. Proc Soc Exp Biol Med 1960; 105: 453-455 15 Kraut H, Frey EK, Bauer E. Über ein neues Kreislaufhormon. II. Mitteilung. Hoppe-Seylers Zeitschr. Physiol. Chem 1928; 175: 97-114 16 Vogt W. Demonstration of the presence of two separate kininforming systems in human and other plasma. In Erdos EG, Back N, Sicuteri F. "Hypotensive Peptides,". New York: Springer Verlag: 1966. pp 185-192 17 Jacobsen S, Kriz M. Some data on two purified kininogens from human plasma. Brit J Pharmacol 1967; 29: 25-36 18 Margolis J. Plasma pain-producing substance and blood clotting. Nature (London) 1957; 180: 1464-1465 19 Webster ME, Ratnoff OD. Role of Hageman factor in the activation of vasodilator activity in human plasma. Nature (London) 1961; 192: 180-181 20 Ratnoff OD. The effect of clotting on the spontaneous activation of plasmin. J Clin Invest 1955; 34: 958-959 (abstr.) 21 Niewiarowski S, Prou-Wartelle O. Rôle du facteur contact (facteur Hageman) dans la fibrinolyse. Thromb Diath Haemorrh 1959; 3: 593-603 22 Iatridis SG, Ferguson JH. Effect of surface and Hageman factor on the endogenous or spontaneous activation of the fibrinolytic system. Thromb Diath Haemorrh 1961; 6: 411-423 23 Ogston D, Ogston CM, Ratnoff OD, Forbes CD. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest 1969; 48: 1786-1801 24 Kaplan AP, Austen KF. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med 1972; 136: 1378-1393 25 Laake K, Vennerod AM. Factor XII-induced fibrinolysis: studies on the separation of prekallikrein, plasminogen proactivator, and factor XI in human plasma. Thromb Res 1974; 4: 285-302 26 Bouma BM, Griffin JH. Human prekallikrein (plasminogen proactivator): purification, characterization and activation by activated factor XII. Thromb Haemostasis 1977; 38: 136 (abstr.) 27 Vennerod AM, Laake K. Prekallikrein and plasminogen proactivator: absence of plasminogen proactivator in Fletcher factor deficient plasma. Thromb Res 1976; 8: 519-522 28 Mandle Jr R, Kaplan AP. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 1977; 252: 6097-6104 29 Saito H. The participation of plasma Thromboplastin antecedent in contact mediated fibrinolysis. Proc Soc exp Biol (in press) 30 Goldsmith Jr GH, Saito H, Ratnoff OD. The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J Clin Invest 1978; 62: 54-60 31 Schiffman S, Lee P. Partial purification and characterization of contact activation cofactor. J Clin Invest 1975; 56: 1082-1093 32 Schiffman S, Lee P. Preparation, characterization, and activation of a highly purified factor XI: evidence that a hitherto unrecognized plasma activity participates in the interaction of factors XI and XII. Brit J Haemat 1974; 27: 101-114 33 Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood 1965; 26: 521-532 34 Waldman R, Abraham JP, Rebuck JW, Caldwell J, Saito H, Ratnoff OD. Fitzgerald factor: a hitherto unrecognized clotting factor. Lancet 1975; 1: 949-951 35 Saito H, Ratnoff OD, Waldmann R, Abraham JP. Fitzgerald trait. Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability. J Clin Invest 1975; 55: 1082-1089 36 Wuepper KD. Biochemistry and biology of components of the plasma kinin-forming system. In: Lepow IH, Ward PA. "Inflammation: Mechanisms and Control,". New York: Academic Press: 1972. pp. 93-117 37 Wuepper KD, Miller DR, Lacombe M-J. Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 1975; 56: 1663-1672 38 Donaldson VH, Glueck HI, Miller MA, Movat HA, Habal F. Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis. J Lab Clin Med 1976; 87: 327-337 39 Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-1662 40 Saito H, Ratnoff OD. Molecular heterogeneity of human plasma prekallikrein deficiency (Fletcher trait). Clin Res 1977; 25: 347 A 41 Donaldson VH, Ratnoff OD. Hageman factor: alterations in physical properties during activation. Science 1965; 150: 754-756 42 Schoenmakers JG G, Matze R, Haanen C, Zilliken F. Hageman factor, a novel sialoglycoprotein with esterase activity. Biochem Biophys Acta 1965; 101: 166-176 43 Revak SD, Cochrane CP, Johnston AR, Hugli TE. Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest 1974; 54: 619-627 44 Kaplan AP, Austen KF. A pre-albumin activator of prekallikrein. J Immunol 1970; 105: 802-811 45 Fujikawa K, Walsh KA, Davie EW. Isolation and characterization of bovine factor XII (Hageman factor). Biochem 1977; 16: 2270-2278 46 Fujikawa K, Kurachi K, Davie EW. Characterization of bovine factor XIIa (activated Hageman factor). Biochem 1977; 16: 4182-4188 47 Ratnoff OD, Crum JD. Activation of Hageman factor by solutions of ellagic acid. J Lab Clin Med 1964; 63: 359-377 48 Hardisty RM, Margolis J. The role of Hageman factor in the initiation of blood coagulation. Brit J Haemat 1959; 5: 203-211 49 Vroman L. Effect of hydrophobic surfaces upon blood coagulation. Thromb Diath Haemorrh 1964; 10: 455-493 50 McMillin CR, Saito H, Ratnoff OD, Walton AG. The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents. J Clin Invest. 1974; 54: 1312-1322 51 Fair BD, Saito H, Ratnoff OD, Rippon WB. Detection by fluorescence of structural changes accompanying the activation of Hageman factor (factor XII). Proc Soc Exp Biol Med 1977; 155: 199-202 52 Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest 1977; 59: 1167-1175 53 Ratnoff OD, Saito H. Amidolytic properties of single-chain activated Hageman factor. Proc Natl Acad Sci USA 1979; 76: 1461-1463 54 Ratnoff OD, Saito H. Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen and plasma thromboplastin antecedent. Proc Natl Acad Sci USA 1979; 76: 958-961 55 Saito H. Purification of high molecular weight kininogen and the role of this agent in blood coagulation. J Clin Invest 1977; 60: 584-594 56 Schiffman S, Lee P, Waldmann R. Identity of contact activation cofactor and Fitzgerald factor. Thromb Res 1975; 6: 451-454 57 Wiggins RC, Bouma BN, Cochrane CG, Griffin JH. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc Natl Acad Sci 1977; 74: 4636-4640 58 Donaldson VH, Kleniewski J, Saito H, Sayed JK. Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma. J Clin Invest 1977; 60: 571-583 59 Mandle RJ, Coleman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976; 73: 4179-4183 60 Thompson RE, Mandle Jr R, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-1380 61 Ratnoff OD, Saito H. Evidence that Fitzgerald factor counteracts inhibition by kaolin or ellagic acid of the amidolytic properties of a plasma kallikrein. Blood 1976; 47: 243-251 62 Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med 1973; 138: 1564-1583 63 Ratnoff OD, Saito H. The countervailing effect of high molecular weight (HMW) kininogen upon inhibition by kaolin of Hageman factor (factor XII, HF) and HF fragments (HFf). Blood 52, Suppl 1978; 1: 351 (abstr.)
